Research at MIND
Locations
FAQ
Join in the QUEST
Facility Description
Performance Metrics
Alzheimer's Disease
Cervical Dystonia
Diabetes
Diabetic Neuropathy
Gout
Hypertension
Low Back Pain
Multiple Sclerosis Spasticity
Osteoarthritis
Parkinson’s Disease
Postherpetic Neuralgia (PHN / Pain after Shingles)
Restless Legs Syndrome (RLS)
Rheumatoid Arthritis
Women's Low Sex Drive
Recent Post
GlaxoSmithKline and XenoPort Receive FDA Approval for Horizant(TM) as new treatment for moderate-to-severe primary Restless Legs Syndrome
More positive data from a clinical trial at QUEST…
BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data in Phase III Program
Impax Pharmaceuticals Announces IPX066 Demonstrates Efficacy and Safety in APEX-PD Phase III Study in Treatment of Early Parkinson’s Disease
BOTOX(R) (onabotulinumtoxinA) FDA Approved as Prophylactic Treatment Option for Adult Chronic Migraine Sufferers
Pages
About us
Locations
Research at MIND
Contact Us
Download
Download our free guide and reports
Industry Professionals
Facility Description
Performance Metrics
Links
New Research
News
Privacy Policy
Resources
Study Participants
FAQ
Join in the QUEST
testing
testing page
Thank You!
Welcome
Current Studies
Alzheimer’s Disease
Cervical Dystonia
Diabetes
Diabetic Neuropathy
Gout
Hypertension
Low Back Pain
Multiple Sclerosis Spasticity
Osteoarthritis
Parkinson’s Disease
Postherpetic Neuralgia (PHN / Pain after Shingles)
Restless Legs Syndrome (RLS)
Rheumatoid Arthritis
Women’s Low Sex Drive
5
Unique
Visitors
Powered By
Categories
Uncategorized
BioSante Pharmaceuticals Reports Positive LibiGel[R] Safety Data in Phase III Program
January 28th, 2010 Posted by admin | Posted in
Uncategorized
|
No Comments »
read story
view video on the Bloom Study
Newer Entries »
